NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the 2015 Stifel Healthcare Conference.
Clearside Biomedical, Inc. Announces Fifth Patent Issued in the U.S. Related To Proprietary Microneedle Drug Delivery Methods and Devices
ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside Biomedical, a clinical-stage biopharmaceutical company developing drug therapies for the eye, announces fifth patent issued in U.S. relating to its proprietary SCS™ drug delivery technology.
Inotek Pharmaceuticals Corporation Reports Third Quarter 2015 Financial Results and Operational Highlights
LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek Pharmaceuticals Corporation Reports Third Quarter 2015 Financial Results and Operational Highlights
AAO announces launch of new online resource to improve eye care for children
The American Academy of Ophthalmology today announced the launch of a new online resource for eye physicians and surgeons dedicated solely to children’s ocular diseases and disorders. The Knights Templar Eye Foundation Pediatric Ophthalmology Education…
New risk tools spot patients at high risk of diabetes complications
Two new risk prediction tools can identify patients with diabetes who are at high risk of blindness and amputation – two serious complications of diabetes, finds a study published in The BMJ this…
Vision Medicines, Case Western enter licensing agreement for VM200 for Stargardt disease
Vision Medicines has entered into an exclusive worldwide licensing agreement with Case Western Reserve University for VM200, an oral small molecule drug candidate for the treatment of Stargardt disease, according to a press release. “We are enthusiastic about the potential for VM200 and have initiated investigational new drug application-enabling studies to advance VM200 into a phase 1/2 program for Stargardt disease in 2016,” Chris Varma, PhD, chairman and CEO of Vision Medicines, said in the release.